Prescription Strategies of Amikacin in Intensive Care Patients on Renal Replacement Therapy: an Observational Prospective Multicenter Study

Amikacin Treatment Clinical Trial

— AMIDIAL-ICU  

Official title:

Prescription Strategies of Amikacin in Intensive Care Patients on Renal Replacement Therapy: an Observational Prospective Multicenter Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04322019
• Other study ID #: PO20032
• Status: Completed
• Start date: May 25, 2020
• Est. completion date: May 16, 2022

Study information

• Verified date: June 2022
• Source: CHU de Reims
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Amikacin is the aminoglycoside of choice for treatment of severe infections in intensive care. An achievement of its objectives in pharmacokinetics and pharmacodynamics is difficult in intensive care patients because of modification of their volume of distribution and renal clearance. Acute renal failure requiring renal replacement therapy is frequent in intensive care. Extrarenal purification modalities (continuous versus intermittent, type of dialysis membrane), which can influence amikacin clearance, are multiple and teams dependent. Guidelines of good practice for Amikacin in intensive care patients do not exist.

Description:

The aim of this study is to describe strategies of prescription and monitoring of Amikacin in intensive care patients on renal replacement therapy.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 112
• Est. completion date: May 16, 2022
• Est. primary completion date: February 16, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

inclusion criteria :

• patients in intensive care

• patients on extrarenal replacement

• patients with Amikacin treatment

• patients accepting to participate in the study

exclusion criteria :

• patients less than 18 years old

• pregnant women

• patients with Amikacin treatment in the previous 7 days

Related Conditions & MeSH terms

• Amikacin Treatment

Intervention

Other:
• Data record
Data record

Locations

Country	Name	City	State
France	Damien JOLLY	Reims

Sponsors (1)

Lead Sponsor	Collaborator
CHU de Reims

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Measurement of maximum concentration observed	Monitoring of Amikacin treatment using measurement of maximum concentration observed performed or not	Day 0